GRETeL: Tumor Response to Standard Radiotherapy and TMZ Patients With GBM
A Study for Patients Newly Diagnosed With Glioblastoma Being Treated With Standard Radiotherapy and Temozolomide (TMZ) to Evaluate Tumor Response Via Liquid Biopsies (GRETeL)
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Mustafa Khasraw, MBChB, MD, FRCP, FRACP
- Phone Number: 919-684-5301
- Email: dukebrain1@dm.duke.edu
Study Contact Backup
- Name: Stevie Threatt
- Phone Number: 919-684-5301
- Email: dukebrain1@dm.duke.edu
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- The Preston Robert Tisch Brain Tumor Center at Duke University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age ≥ 18 years
- Patients newly diagnosed with malignant glioma, IDH wildtype who have undergone surgical resection for their tumor and who are planned for standard of care radiation therapy with concurrent temozolomide (i.e., at least 59 Gy in 30 fractions over 6 weeks)
- Patients must have leftover tissue available from the surgical resection of their tumor available to request for this research.
- Able to undergo MRI of brain with and without contrast
- Signed informed consent approved by the Institutional Review Board (IRB)
Exclusion Criteria:
- Prior, unrelated malignancy requiring current active treatment with the exception of cervical carcinoma in situ and adequately treated basal cell or squamous cell carcinoma of the skin
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Pilot
The first 20 patients accrued to this study will be assayed to validate the performance of the assays developed by Personalis.
This pilot sub-study will be analyzed in a "blinded" manner without clinical information.
|
|
Full Study
The remaining 80 patients accrued to this study (after the initial 20 patients accrue to the "Pilot" cohort).
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Median cf/ctDNA concentration at pre- and post-radiation, as well as median change in ct/ctDNA concentration
Time Frame: 6 months
|
Identify and describe changes in the cell free DNA (cfDNA) sequencing profiles of patients diagnosed with GBM in pre- versus post-radiation therapy samples, and to assess the association between these changes and clinical outcome, including progression free and overall survival
|
6 months
|
|
Median levels of cfDNA collected longitudinally after completion of radiation
Time Frame: 6 months
|
Identify and describe changes over time after radiotherapy in the cfDNA sequencing profiles of patients diagnosed with GBM, and to assess the association between these longitudinal changes in cfDNA and clinical outcome, including progression free and overall survival
|
6 months
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Characterize the fragmentomic landscape of GBM
Time Frame: 6 months
|
Median number of ctDNA fragments obtained from tumor tissue, pre-radiation serum specimen, and post-radiation serum specimen, and healthy controls.
|
6 months
|
|
Spearman correlation between clinical descriptors and measures of ctDNA
Time Frame: 6 months
|
Assess the association between degree and frequency of ctDNA shedding and clinical characteristics, such as molecular findings, histopathological characteristics, corticosteroid use, and bevacizumab use.
|
6 months
|
|
Median and range for measures of tumor immune infiltration
Time Frame: 6 months
|
Quantify the level of immune infiltration in the tumor, and assess its association with progression-free survival (PFS), overall survival (OS), and ctDNA detection.
|
6 months
|
|
Hazard ratio for the relationship between chromosomal instability and OS or PFS
Time Frame: 6 months
|
Assess the prognostic value of chromosomal instability/CAN burden, and assess its association with ctDNA from plasma.
|
6 months
|
|
Spearman correlation between ctDNA and peripheral T cell function, autoantibodies.
Time Frame: 6 months
|
Determine if peripheral T cell function and stemness or autoantibodies are association with ctDNA levels, or TME composition.
|
6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Mustafa Khasraw, MBChB, MD, FRCP, FRACP, Duke University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Pro00110247
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.